Novo Slides 14% as Early Q4 Results Predict Sales Decline for 2026

Novo Nordisk, the Danish pharmaceutical giant, is bracing for a challenging 2026. The company announced Tuesday that its sales are projected to decline by 5% this year—a shift attributed to lower drug prices in the U.S. This preview of full-year results came ahead of the official earnings report scheduled for Wednesday.

A Sales Reversal for a Pharma Leader

Despite beating analyst expectations for the fourth quarter of 2025, Novo Nordisk’s forecast for 2026 has rattled investors. Shares fell 14% on Tuesday, closing at $50.54 compared to $58.93 the previous day. The downturn follows a period of significant success for the company, with CEO Maziar Mike Doustdar calling the launch of its weight loss drug, Wegovy, “the most successful pharma launch ever.”

Did You Know? Over 100,000 Americans are currently taking Novo Nordisk’s Wegovy pill.

GLP-1s and the Pricing Landscape

Novo Nordisk’s diabetes drug, Ozempic, generated $32.2 billion in the fourth quarter, reaching $127.1 billion for the entire year. Weight loss therapy Wegovy brought in $21.9 billion in the last quarter of 2025, totaling $79.1 billion for the year. These figures demonstrate the strong performance of Novo Nordisk’s semaglutide franchise, with Ozempic becoming the second-best-selling drug of 2024 with $16.9 billion in sales—a figure it exceeded in 2025.

The anticipated sales decline is linked to pricing pressures stemming from agreements made with the White House in November 2025, where Novo Nordisk and Eli Lilly committed to lowered prices for their GLP-1 products. BMO Capital Markets noted that these challenges are partially offset by a reversal of rebating provisions through the 340B Drug Pricing programme, which is expected to positively impact sales and operating profit by $4.2 billion.

Expert Insight: The projected sales decline highlights the growing influence of drug pricing regulations and negotiations on the pharmaceutical industry’s revenue streams, potentially reshaping market dynamics in the coming years.

What’s Next for Novo Nordisk?

Despite the challenges, Novo Nordisk remains optimistic. Doustdar emphasized the vast potential market, stating that “There will soon be 2 billion people globally living with obesity, overweight or diabetes, and our ambition is to serve as many of these people as possible.” The company is also anticipating the launch of an oral version of Wegovy, which investors will be closely watching. BMO Capital Markets expects investors to seek further clarification on the guidance change and assumptions for the GLP-1 franchise during tomorrow’s earnings report.

Frequently Asked Questions

What is driving the expected sales decline for Novo Nordisk in 2026?

Lower drug prices in the U.S., resulting from agreements with the White House, are expected to cause a 5% decline in sales.

How did Novo Nordisk perform in 2025?

Novo Nordisk beat analyst expectations in the fourth quarter of 2025, with strong sales of both Ozempic and Wegovy.

What is Novo Nordisk’s outlook for the future?

Despite the projected decline, Novo Nordisk remains confident in its ability to serve the growing global market for obesity and diabetes treatments.

As Novo Nordisk navigates these shifting market conditions, how might evolving drug pricing policies impact the broader pharmaceutical landscape and access to innovative medications?